Pipeline

The current advanced pipeline includes Androgen Restored Contraception (ARC), Estetrol (E4) and Zona Pellucida (ZP) immunotherapy (antigen immunisation). ZP for ovarian cancer has been sold to HRA Pharma (France) in October 2014, whereas the other applications were retained by PRB. All rights on E4 have been sold to Mithra Pharmaceuticals (Belgium) in March 2015, whereas PRB has exclusively licensed back the rights on oncological and veterinary applications. PRB has founded a subsidiary company – Pantarhei Oncology (PRO) – to develop oncological treatments with a current focus on breast and prostate cancer.

Androgen Restored Contraception (ARC)
E4 - Oncology
 
E4 - Veterinary use
 
ZP - Immunization
 

Research

 
 
 
 
 
 
 
 

Pre-clinical / GLP-tox

 
 
 
 
 
 
 
 

Clinical / Phase I

 
 
 
 
 
 
 
 

Clinical / Phase II

 
 
 
 
 
 
 
 

Clinical / Phase III